To unsubscribe from future Motegrity communications, please fill in the required fields, and click SUBMIT.
*= Required field
Your request to unsubscribe has been received and is being processed.
Please allow up to 10 business days to process your request.
You may receive additional communications during this period.
THIS SITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY
© 2023 Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421. All rights reserved. 1-877-TAKEDA-7 (1-877-825-3327). MOTEGRITY® and the MOTEGRITY Logo® are registered trademarks of Takeda Pharmaceuticals U.S.A., Inc. TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited. US-PRU-0728v1.0 03/23
All content of this website, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Takeda and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites. This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Takeda makes reasonable efforts to include accurate, up-to-date information on this site, Takeda makes no warranties or representations as to its accuracy. Takeda assumes no liability for any errors or omissions in the content of this site. The information on this site is not intended to make a diagnosis or to take the place of talking to a US health care professional.
Contraindications
Warnings and Precautions
Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.
Adverse Reactions
Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.
Use in Specific Populations
INDICATION
Motegrity® (prucalopride) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Please click here for full Prescribing Information.
Please note that Takeda is not responsible or liable for any third party website and the website may not be appropriate for all audiences.